Loading...
Takeda Pharmaceutical Company Limited
4502.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥4217.00
¥17.00(0.40%)
Takeda Pharmaceutical Company Limited (4502.T) Financial Performance & Income Statement Overview
Review Takeda Pharmaceutical Company Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
7.45%
↑ 7.45%
Operating Income Growth
144.36%
↑ 144.36%
Net Income Growth
-25.08%
↓ 25.08%
Operating Cash Flow Growth
34.36%
↑ 34.36%
Operating Margin
9.62%
↑ 9.62%
Gross Margin
54.70%
↑ 54.70%
Net Profit Margin
2.36%
↑ 2.36%
ROE
1.48%
↑ 1.48%
ROIC
3.75%
↑ 3.75%
Takeda Pharmaceutical Company Limited (4502.T) Income Statement & Financial Overview
Review Takeda Pharmaceutical Company Limited's (4502.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1053.40B | $1144.12B | $1176.04B | $1207.99B |
| Cost of Revenue | $571.85B | $416.87B | $536.73B | $549.78B |
| Gross Profit | $481.55B | $727.25B | $639.31B | $658.21B |
| Gross Profit Ratio | $0.46 | $0.64 | $0.54 | $0.54 |
| R&D Expenses | $216.007B | $170.19B | $175.56B | $168.46B |
| SG&A Expenses | $295.87B | $270.59B | $268.28B | $270.03B |
| Operating Expenses | $511.87B | $660.31B | $443.85B | $438.49B |
| Total Costs & Expenses | $1083.72B | $1077.18B | $980.57B | $988.28B |
| Interest Income | $18.74B | -$6.99B | $4.12B | $30.68B |
| Interest Expense | $50.32B | $31.60B | $68.45B | $59.69B |
| Depreciation & Amortization | $189.77B | $186.96B | $192.45B | $192.22B |
| EBITDA | $146.89B | $244.96B | $380.28B | $384.55B |
| EBITDA Ratio | $0.14 | $0.21 | $0.32 | $0.32 |
| Operating Income | -$30.32B | $66.94B | $184.25B | $219.71B |
| Operating Income Ratio | -$0.03 | $0.06 | $0.16 | $0.18 |
| Other Income/Expenses (Net) | -$76.19B | -$40.53B | -$64.88B | -$82.40B |
| Income Before Tax | -$106.51B | $26.41B | $119.37B | $137.32B |
| Income Before Tax Ratio | -$0.10 | $0.02 | $0.10 | $0.11 |
| Income Tax Expense | -$4.20B | $2.57B | $27.27B | $41.30B |
| Net Income | -$103.16B | $23.79B | $92.05B | $95.25B |
| Net Income Ratio | -$0.10 | $0.02 | $0.08 | $0.08 |
| EPS | -$65.25 | $15.03 | $58.14 | $60.71 |
| Diluted EPS | -$65.25 | $14.78 | $57.17 | $59.94 |
| Weighted Avg Shares Outstanding | $1.58B | $1.59B | $1.58B | $1.57B |
| Weighted Avg Shares Outstanding (Diluted) | $1.58B | $1.63B | $1.61B | $1.59B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan